East Coast insurer now covers tibial nerve stimulation for OAB
Uroplasty, Inc. has announced that EmblemHealth now covers percutaneous tibial nerve stimulation using the company's Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
Uroplasty, Inc. has announced that EmblemHealth now covers percutaneous tibial nerve stimulation using the company’s Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
EmblemHealth covers approximately two million lives primarily in New York and New Jersey and includes Group Health Inc. and the Health Plan of New York.
“This expanded private payer coverage increases access for OAB patients to percutaneous tibial nerve stimulation treatments and the opportunity to receive this innovative, minimally invasive, and clinically effective therapy. The additional coverage provides physicians in the Northeast with another treatment option for their OAB patients,” said David Kaysen, president and CEO of Uroplasty.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
